LONDON, Jan. 15, 2018 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5284469
Summary
Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organization's (WHO's) classification of the different types of pulmonary hypertension (PH). PAH is characterized by an abnormal rise in the resting mean pulmonary artery pressure (PAP) (>25mmHg compared with normal levels of around 14mmHg), a pulmonary vascular resistance of more than 3 Wood units, and a pulmonary capillary wedge pressure less than 15mmHg (Foshat and Boroumand, 2017). Pulmonary arterial hypertension (PAH) market has generated much interest and investment from drug developers over the past several years, despite PAH being a rare disease. Current treatments include 13 marketed drugs from five different therapeutics classes, while there are four drugs in late-stage development. The forecast period from 2016-2026 will be marked by the patent expirations of several of these marketed drugs, including Volibris/Letairis, Opsumit, Adcirca, Adempas, Remodulin, Tyvaso, and Uptravi. It is estimated that the 2016 sales for the pulmonary arterial hypertension (PAH) market was approximately $3.8B across the 7MM, encompassing the US, the five major European countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. By 2026, it is expected that the overall market will grow at a moderate compound annual growth rate (CAGR) of 2.2% over the 10-year period. Major drivers to this growth in the PAH market during the forecast period will include -
- Increased use of combination therapy following the positive outcomes from recent clinical trials will boost PAH sales due to higher treatment costs of drug combinations. - Launch of Reata Pharmaceuticals' first-in-class antioxidant inflammation modulator, bardoxolone methyl, will provide an effective oral therapy for PAH patients with the potential of being used in combination with other therapies. - Patient assistance programs by manufacturers will provide reimbursement support to the patients. - Launch of Arena Pharmaceuticals' pipeline drug, ralinepag, will provide an effective oral alternative to parenteral prostacyclin therapy. The report "OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecasts to 2026", provideoverview of pulmonary arterial hypertension, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. In particular, this report provides the following -
- Annualized PAH therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PAH therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global PAH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Companies mentioned in this report: Actelion Pharmaceuticals (now key subsidiary of Johnson & Johnson), Arena Pharmaceuticals Bayer, EigerBioPharmaceuticals, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Mochida Pharmaceutical. Scope
- Overview of pulmonary arterial hypertension, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized PAH therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PAH therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global PAH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy
The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global PAH therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAH therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global PAH therapeutics market from 2016-2026. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Download the full report: https://www.reportbuyer.com/product/5284469
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected] Tel: +1 (646) 453 6293 Website: www.reportbuyer.com
Advertisement
View original content:http://www.prnewswire.com/news-releases/opportunityanalyzer-pulmonary-arterial-hypertension---opportunity-analysis-and-forecasts-to-2026-300582696.html
SOURCE ReportBuyer
